Soleno Therapeutics (SLNO) Interest Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) reported Interest Expenses of $1.3 million for Q1 2026, down 5.07% year-over-year from $1.4 million in Q1 2025, and down 4.23% quarter-over-quarter from $1.3 million in Q4 2025.

Soleno Therapeutics (SLNO) Interest Expenses (2013 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of Interest Expenses data on file, last reported at $1.3 million in Q1 2026.

  • Interest Expenses for Q1 2026 came in at $1.3 million, down 5.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (up 297.28% YoY), and the FY2025 annual result was $5.5 million, up 2270.56% from the prior year.
  • Interest Expenses eased to $1.3 million in Q1 2026 per SLNO's latest filing, from $1.3 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $1.4 million in Q3 2025 and troughed at $1.3 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int Expense (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -5.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -332,000.00
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 61,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -2,753.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -5.58 Mn
10 Soleno Therapeutics 2.76 Bn 2.51 Bn 93.41 Mn 1.29 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.29 Mn
Mar 31, 2026 1.29 Mn
Dec 31, 2025 1.35 Mn
Dec 31, 2025 1.35 Mn
Sep 30, 2025 1.39 Mn
Sep 30, 2025 1.39 Mn
Jun 30, 2025 1.38 Mn
Jun 30, 2025 1.38 Mn
Mar 31, 2025 1.36 Mn
Mar 31, 2025 1.36 Mn
Dec 31, 2015 -1,000.00
Dec 31, 2015 -1,000.00
Mar 31, 2015 1,000.00
Mar 31, 2015 1,000.00
Dec 31, 2014 2.32 Mn
Dec 31, 2014 2.32 Mn
Sep 30, 2014 752,000.00
Sep 30, 2014 752,000.00
Jun 30, 2014 670,000.00
Jun 30, 2014 670,000.00